

**ISSN**INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIAISSN No. : 2584-2757
Volume : 04
Issue : 01Publisher
ROGANIDAN VIKRUTIVIGYAN PG ASSOCIATION
FOR PATHOLOGY AND RADIODIGNOSIS
Reg. No. : MAHA-703/16(NAG) Year of Establishment – 2016

DOI :10.5281/zenodo.23435217

ISI Impact Factor (2025-26): 1.345
IIFS Impact Factor (2026-27): 6.0

INTERNATIONAL JOURNAL OF DIAGNOSTICS AND RESEARCH

Explanatory and Conceptual Study of Vātarakta (Pathogenesis and Management) with Special Reference to the Bṛhat-trayī and Special Emphasis on Charaka Saṃhitā

Dr. Vishwanath B. Kakde¹

¹ Associate Professor, Department of Samhita-Siddhanta & Sanskrit, Future Institute of Ayurvedic Medical Sciences, Bareilly, Uttar Pradesh, India

Corresponding Author: Dr. Vishwanath Kakde**ORCID ID:****Article Info:** Article Received on : 08/10/2026

Article Reviewed on: 10/10/2026

Article Published on : 15/10/2026

Cite this article as: - Kakde V. Explanatory and Conceptual Study of Vātarakta (Pathogenesis and Management) with Special Reference to the Bṛhat-trayī and Special Emphasis on Charaka Saṃhitā. International Journal of Diagnostics And Research. 2026Oct17;4(1):104–15. doi:10.5281/zenodo.23435217

Abstract

Background: *Vātarakta* is a complex, progressive clinico-pathological entity in *Ayurveda* characterized by the simultaneous aggravation and profound interaction of *Vāta Doṣa* and *Rakta Dhātu*. While contemporary biomedical science often correlates it broadly with gout and inflammatory arthropathies, the classical *Ayurvedic* treatises (*Bṛhat-trayī*) elucidate a highly specific pathogenesis rooted in *Mārga Avarodha* (channel obstruction) and sequential *Doṣa-Dūṣya Saṃmūrchana*. Despite extensive descriptions in classical texts, a critical, comparative synthesis prioritizing Charaka Saṃhitā's foundational pathophysiological architecture remains inadequately explored in modern literature.

Objective: To critically analyse and conceptually synthesize the *Nidāna* (etiology), *Samprāpti* (pathogenesis), *Bheda* (classification), and *Chikitsā* (management) of *Vātarakta* as described in the *Bṛhat-trayī*, with a special emphasis on *Charaka Saṃhitā*, and to evaluate its contemporary relevance to inflammatory arthropathies.

Materials and Methods: A qualitative textual analysis and comparative conceptual synthesis were conducted. Primary data were extracted from the *Charaka Saṃhitā*, *Suśruta Saṃhitā*, and *Aṣṭāṅga Hṛdaya* alongside their authoritative commentaries. Secondary data included Scopus and PubMed-indexed peer-reviewed publications. The evidence was hierarchically categorized to strictly delineate classical textual statements from modern pathophysiological interpretations.

Results: *Charaka Saṃhitā* establishes a unique paradigm wherein *Vātarakta* is neither exclusively a *Vāta* disorder nor solely a *Rakta* disorder, but a discrete entity arising from bidirectional pathological obstruction (*Avarodha*). The comparative analysis reveals that while *Charaka* emphasizes the systemic metabolic and circulatory interaction (*Vāta-Rakta Saṃmūrchana*), *Suśruta* elaborates on structural and surgical dimensions (*Raktamokṣaṇa*), and *Vāgbhaṭa* provides a highly structured clinico-therapeutic synthesis. A reconstructed *Samprāpti* model links dietary indiscretions directly to *Srotoduṣṭi* and *Sthāna Saṃśraya* in the distal joints.

Conclusion: *Vātarakta* represents an autonomous, multidimensional disease model. *Charaka's* conceptualization emphasizes the restoration of *Vāta gati* (movement) and *Rakta prasādana* (blood purification) through stage-specific *Śodhana* and *Śamana*. While presenting overlapping phenotypes with modern gout (hyperuricemia), *Vātarakta* encapsulates a broader spectrum of neuro-vascular and inflammatory pathologies.

Keywords: *Vātarakta*, *Charaka Saṃhitā*, *Bṛhat-trayī*, Pathogenesis (*Samprāpti*), Gout, Inflammatory Arthropathy, *Mārga Avarodha*.

Introduction :

In the paradigm of Ayurvedic nosology, Vātarakta represents one of the most intricate examples of Doṣa-Dūṣya interaction, characterized by the simultaneous vitiation of Vāta Doṣa and Rakta Dhatu (blood tissue) ^[1]. Described prominently within the Bṛhat-trayī (Charaka Saṁhitā, Suśruta Saṁhitā, and Aṣṭāṅga Hṛdaya), the condition is marked by severe, excruciating pain, inflammation, and eventual joint deformity. Historically, Charaka dedicated a comprehensive chapter to Vātarakta (Charaka Cikitsā Sthāna Adhyāya 29), underscoring its clinical gravity and the necessity of specialized interventions distinct from general Vātavyādhi (neurological/musculoskeletal disorders) ^[1, 2].

The classical text describes the disease pathology as the occlusion of Vāta by vitiated Rakta, leading to a cascade of *Mārga Avarodha* (obstruction in the channels), which forces the aggravated Doṣa to lodge in the extremities (*Pādāmūla* or *Karamūla*), subsequently spreading throughout the body "like rat poison" (*Ākhuviṣavat*) ^[1, 3]. Contemporary biomedical paradigms often interpret Vātarakta strictly as gouty arthritis or hyperuricemia ^[4, 5]. However, limiting Vātarakta merely to monosodium urate crystal deposition compromises the profound vascular, metabolic, and neuro-inflammatory framework conceptualized by ancient scholars. An authentic appraisal requires critically distinguishing between textual statements, conceptual interpretations, and modern correlations.

Aim :

To critically analyse and conceptually synthesize

the Nidāna, Samprāpti, Bheda, and Chikitsā of Vātarakta described in the Bṛhat-trayī, with particular emphasis on Charaka Saṁhitā, and to rigorously examine its relevance in the context of contemporary understanding of inflammatory arthropathies.

Objectives :

1. To identify the primary etiological factors (Nidāna) and classify them systematically based on the Bṛhat-trayī.
2. To analyse the distinct pathophysiological progression (Samprāpti) of Vātarakta, mapping the specific roles of Mārga Avarodha and Srotoduṣṭi.
3. To compare the clinical descriptions, classifications (Bheda), and therapeutic principles across Charaka Saṁhitā, Suśruta Saṁhitā, and Aṣṭāṅga Hṛdaya.
4. To evaluate the linkage between the classical pathogenesis of Vātarakta and its targeted stage-specific management (Chikitsā).
5. To synthesize an integrated conceptual pathophysiological model of Vātarakta.
6. To correlate the classical entity of Vātarakta with modern biomedical equivalents (like gout) while preserving disease individuality.

Research Questions :

1. What are the principal Nidāna of Vātarakta described in the Bṛhat-trayī, and how do they simultaneously vitiate Vāta and Rakta?
2. How does Charaka conceptualize the bidirectional interaction of Vāta and Rakta compared to other classical authors?

- What are the core similarities and differences in Samprāpti and Bheda among the Bṛhat-trayī texts?
- How do different stages (Uttāna and Gambhīra) manifest clinically, and how do these dictate therapeutic modifications?
- How does the Chikitsā Siddhānta (treatment principle) directly correspond to the underlying Samprāpti?
- What is distinctive about Charaka's therapeutic approach to Vātarakta?
- To what extent can Vātarakta be scientifically correlated with modern gout, and where do the phenomenological boundaries diverge?

Materials And Methods :

Study Design: Conceptual, textual, and explanatory research study.

Research Approach: Qualitative textual analysis with comparative conceptual synthesis.

Primary Sources: Charaka Samhitā, Suśruta Samhitā, and Aṣṭāṅga Hṛdaya, alongside authoritative Sanskrit commentaries (e.g., Āyurveda Dīpikā, Nibandha Saṃgraha, Sarvāṅgasundarā).

Secondary Sources: Peer-reviewed scientific publications, systematic reviews, and relevant biomedical literature retrieved from Scopus and PubMed.

Search Strategy: Digital databases were queried using the terms: “Vatarakta”, “Vātarakta”, “Vatashonita”, “Charaka Samhita Vatarakta”, “Vatarakta pathogenesis”, “Vatarakta gout”, and “Vatarakta hyperuricemia”.

Inclusion Criteria: Authoritative classical Ayurvedic texts, recognized Sanskrit commentaries, peer-reviewed scientific publications (last 10 years for biomedical correlation), and studies directly related to Vātarakta pathology and management.

Exclusion Criteria: Unverifiable sources, anonymous websites, non-scholarly blogs, duplicate publications, and AI-generated references lacking verifiable indexing.

Evidence Hierarchy:

- Level I: Direct classical textual evidence.
- Level II: Classical commentary-based interpretation.
- Level III: Author's conceptual synthesis.
- Level IV: Contemporary biomedical correlation.

Classical Textual Analysis :

Charaka frames Vātarakta as a consequence of a physiological paradox: a delicate constitution (Sukumāra) engaging in sedentary habits, coupled with an aggravating, incompatible diet ^[1]. Suśruta addresses Vātarakta as Vātaśonita in Nidāna Sthāna Adhyāya 1, categorizing it alongside structural and neurological deficits, while Vāgbhaṭa places it deliberately post-Vātavyādhi, reflecting an advanced clinico-therapeutic taxonomy ^[2, 3].

Table 1: Bṛhat-trayī textual sources for Vātarakta

Compendium	Sthāna	Adhyāya	Key Focus Area	Reference Nature
Charaka Samhitā	Cikitsā Sthāna	Adhyāya 29	Comprehensive Nidāna, Samprāpti, Bheda, and profound Śodhana/Śamana Chikitsā.	Level I

Compendium	Sthāna	Adhyāya	Key Focus Area	Reference Nature
Suśruta Samhitā	Nidāna Sthāna	Adhyāya 1	Pathophysiology, spatial progression (Pādamūla), surgical aspects.	Level I
Suśruta Samhitā	Cikitsā Sthāna	Adhyāya 5	Raktamokṣaṇa, Lepa, and structural joint management.	Level I
Aṣṭāṅga Hṛdaya	Nidāna Sthāna	Adhyāya 16	Synthesized etiology and clinical presentation.	Level I
Aṣṭāṅga Hṛdaya	Cikitsā Sthāna	Adhyāya 22	Highly structured therapeutic protocols integrating preceding concepts.	Level I

Results :

Classical Textual Findings :

The texts unanimously agree that the simultaneous vitiation of Vāta and Rakta is the sine qua non of the disease. The primary manifestation site is consistently identified as the joints of the extremities, progressing proximalward.

Charaka-Centric Findings:

What is distinctive about Charaka's conceptualization is the Etiological Model of Interaction. Charaka clearly outlines that Vāta and Rakta do not merely coexist in a vitiated state; they actively obstruct each other. Vāta, whose fundamental property is Gati (movement), is physically blocked by the morbidly viscous and inflamed Rakta. This Mārga Avarodha acts as a pathophysiological catalyst, generating intense pain and tissue destruction (Aṅgasāda, Ruk) ^[1].

Comparative Bṛhat-trayī Findings :

While Charaka focuses extensively on the systemic interaction of dietary indiscretion and sedentary lifestyle, Suśruta adds significant weight to trauma and structural precipitants, noting that the disease commonly starts from the feet (Pādamūla) because of gravitational and circulatory properties. Vāgbhāṭa masterfully harmonizes these views, offering precise prognostic guidelines.

Samprāpti Reconstruction

(See Section 12 for the detailed sequence)

Bheda Analysis

(See Section 13 for analysis)

Chikitsā Analysis

(See Section 14 for analysis)

Contemporary Correlation

(See Section 15 for analysis)

Comparative Analysis :

Table 2: Comparative Nidāna (Etiology)

Category	Charaka Samhitā	Suśruta Samhitā	Aṣṭāṅga Hṛdaya	Interpretation (Level III)
Āhāraja (Diet)	Lavana, Amla, Katu, Kṣāra, Snigdha, Uṣṇa. Viruddha Āhāra.	Heavy diets, excessive alcohol, meat of aquatic/marshy animals.	Mirrors Charaka, emphasizes Vidāhī and Amla foods.	Pro-inflammatory diets high in purines, salts, and fats.
Vihāraja (Lifestyle)	Sedentary lifestyle, daytime sleep, riding animals.	Excessive riding, long-distance walking, trauma.	Day sleep, excessive trauma to joints, sedentary habits.	Mechanical stress on dependent joints combined with metabolic stasis.

Category	Charaka Samhitā	Suśruta Samhitā	Aṣṭāṅga Hṛdaya	Interpretation (Level III)
Constitution	Sukumāra (delicate), obese individuals.	Mentions structural vulnerability.	Highlights Sukumāra and Sthūla.	Genetic/constitutional predisposition to metabolic overload.

Table 3: Comparative Samprāpti (Pathogenesis)

Parameter	Charaka Samhitā	Suśruta Samhitā	Aṣṭāṅga Hṛdaya
Initial Stage	Doṣa-Dūṣya interaction and mutual aggravation.	Vāta aggravated by trauma/riding interacts with Rakta.	Synchronized aggravation of both components.
Avarodha Mechanism	Explicitly defines Mārga Avarodha (obstruction of channels by Rakta).	Implies obstruction leading to stasis.	Re-emphasizes Charaka's Avarodha concept.
Direction of Spread	Akhuviṣavāt (like rat poison, spreading insidiously).	Pādāmūla to upward spread.	Matches Suśruta (from feet/hands upwards).

Critical Explanation of Similarities and Differences:

All three texts recognize the primacy of Vāta and Rakta. However, Charaka presents Vātarakta primarily as an obstructive pathology (Mārga Avarodha) where metabolic toxicity impairs circulatory dynamics. Suśruta, being a surgical text, describes it with a biomechanical and anatomical lens, emphasizing weight-bearing joints and trauma. Vāgbhaṭa acts as a synthesizer, seamlessly merging Charaka's metabolic etiology with

Suśruta's anatomical progression.

Samprāpti Analysis (Pathogenesis)

The classical text describes a specific sequence of events. Based on Charaka Samhitā (Cikitsā Sthāna 29/8-11), the author's conceptual reconstruction is as follows:

Author's Conceptual Reconstruction based on Classical Principles (Level III):

1. *Nidāna Sevana*: Consumption of Vidāhī, Amla, Kṣāra foods + Sedentary lifestyle + Mechanical trauma.
2. *Doṣa Prakopa & Rakta Duṣṭi*: Simultaneous aggravation of Vāta (due to trauma/dryness) and Rakta (due to acidic/hot foods).
3. *Mārga Avarodha*: The morbid, heavy Rakta rapidly blocks the subtle channels (Srotas) of Vāta.
4. *Vāta-Rakta Saṁmūrchana*: The obstructed Vāta further aggravates, disrupting the flow of Rakta. They mutually vitiate each other.
5. *Sthāna Saṁśraya*: Due to gravity, vascular anatomy, and structural stress, the complex lodges in the distal extremities (Pāda, Hasta).
6. *Vyakti*: Manifestation of severe pain (Toda, Bheda), inflammation (Śoṭha), and discoloration (Vaivarnya).

Table 4: Samprāpti Ghaṭaka

Samprāpti Ghaṭaka	Classical Reference/Interpretation
Doṣa	Vāta (Vyāna) and Pitta/Kapha (as Anubandha).
Dūṣya	Rakta (primary), Mamsa, Asthi, Majjā, Sandhi (in Gambhīra).
Agni	Jaṭharāgni Māndya, Dhātvaṅni Māndya (metabolic defect).
Ama	Sāma state initially; contributes to Avarodha.
Srotas	Raktavaha, Māmsavaha, Asthivaha.
Srotoduṣṭi	Saṅga (obstruction), Vimārgagamana (diversion of flow).
Udbhava Sthāna	Āmāśaya / Pakvāśaya.
Saṅcāra	Tiryag Gāmi Sirā (peripheral vascular channels).
Sthāna Saṁśraya	Pādamūla, Karamūla, Sandhi (joints).
Rogamārga	Bāhya progressing to Madhyama (Marmāsthisandhi).
Sādhyaśādhya	Kṛcchrasādhya (difficult to cure) to Yāpya/Asādhya if chronic.

Bheda Analysis (Types)

Charaka introduces a profound clinico-pathological classification based on depth (Adhiṣṭhāna) and Doṣa predominance^[1].

Table 5: Comparative Bheda

Type / Stage	Classical Description	Dominant Pathology	Clinical Manifestations	Prognostic Significance
Uttāna (Superficial)	Located in Twak (skin) and Māmsa (muscle).	Microvascular / Cutaneous.	Itching (Kandu), burning, pain, skin discoloration, superficial nodules.	Sādhya (Curable) if treated early.

Type / Stage	Classical Description	Dominant Pathology	Clinical Manifestations	Prognostic Significance
Uttāna (Superficial)	Located in Twak (skin) and Māmsa (muscle).	Microvascular / Cutaneous.	Itching (Kandu), burning, pain, skin discoloration, superficial nodules.	Sādhya (Curable) if treated early.
Gambhīra (Deep)	Located in Dhātus, Asthi, Majjā, Sandhi (joints).	Synovial / Osseous / Articular.	Deep-seated piercing pain, gross swelling, joint deformity, systemic fever.	Kṛcchrasādhya or Yāpya (Palliative).
Vāta-dominant	Characterized by extreme pain and neuro-vascular spasms.	Vāta Prakopa.	Tearing pain, twitching, dryness, stiffness, severe cold sensitivity.	Requires profound Snehana (oleation).
Rakta/Pitta-dominant	Characterized by intense acute inflammation.	Pitta/Rakta Duṣṭi.	Burning sensation, redness, severe tenderness, heat, suppuration.	Requires Raktamokṣaṇa and Śīta Upacāra.
Kapha-dominant	Characterized by structural edema and stasis.	Kapha Avarodha.	Heaviness, cold swelling, numbness, mild pain.	Requires Rūkṣaṇa and Uṣṇa therapies.

Clinical Presentation :

The clinical manifestation follows a definite trajectory.

Table 6: Clinical Manifestations

Stage	Systemic / Local Manifestations	Modern Correlate (Level IV)
Pūrvārūpa (Prodrome)	Hyperhidrosis or anhidrosis, hyperesthesia, formication, joint laxity, discoloration.	Asymptomatic hyperuricemia, early vascular endothelial dysfunction.
Rūpa (Acute)	Sudden onset agonizing pain, localized erythema, burning sensation (Daha), extreme tenderness (Sparśāsahatva).	Acute gouty flare, intense synovial inflammation, podagra.
Chronic Complications	Hard subcutaneous nodules, joint contractures (Khañjatva), structural deformity.	Tophaceous gout, chronic gouty arthropathy, joint destruction.

Chikitsā Analysis (Management)

This is the most strategically profound aspect of Charaka's description. The therapeutic logic dictates that one cannot merely suppress Vāta (which requires heat/oil) because doing so might aggravate Rakta, and vice versa.

A. General Chikitsā Siddhānta

The primary aim is to break the Mārga Avarodha. Charaka advises that Vātarakta should be managed by carefully balancing Rakta-prasādana (blood-purifying) and Vāta-śamana (neuro-vascular pacifying) therapies.

Pathological Component	Therapeutic Target	Classical Intervention	Rationale
Rakta Duṣṭi & Avarodha	Srotoshodhana / Rakta Prasādana	Raktamokṣaṇa (Bloodletting - Jalaukā or Sirāvedha).	Immediately relieves local vascular congestion and expels morbid Rakta [1, 2].
Vāta Prakopa & Pain	Vāta Anulomana / Snehana	Basti (Medicated enemas - Anuvāsana and Niruha).	Basti is the paramount therapy for Vāta. Specifically, Kṣīrabasti (milk-based) pacifies both Vāta and Rakta.
Sāma / Srotoduṣṭi	Āmapācana / Mild Śodhana	Mṛdu Virecana (Mild purgation) using unctuous or dry drugs depending on Dosha.	Clears the gastrointestinal tract and lowers metabolic load (Pitta/Rakta relation).
Local Inflammation	Śothahara / Daha Śamana	Lepa (Poultice) and Pariṣeka (Pouring medicated liquids).	Topical application of cooling, anti-inflammatory herbs (e.g., Daśāṅga Lepa) rapidly reduces local signs.
Chronic Pathology	Śamana / Rejuvenation	Internal administration of Gudūcī and Guggulu.	Gudūcī is the drug of choice (Agya) for Vātarakta due to its immunomodulatory and uricosuric-like actions [6, 7].

Pathya–Apathya (Dietary & Lifestyle Regimen)**Table 8: Pathya–Apathya (Based on Bṛhat-trayī)**

Category	Pathya (Whole some)	Classical Rational e	Apathya (Unwhol esome)	Classic al Ration ale
Āhāra (Diet)	Old wheat, barley (Yava), Sāthi rice, cow's milk, Ghṛta, meat soup of arid animals .	Non-obstructiv e (Srotosho dhaka), balances Vāta without vitiating Rakta.	Kulattha, Urad dal, alkaline foods (Kṣāra), curd, alcohol, heavy meats.	Highly inflam matory, causes Vidāha, increase s Rakta toxicity.
Vihāra (Lifes tyle)	Gentle joint mobilit y, adequat e rest, moderat e climate.	Prevents Srotas stasis.	Day sleep, intense exercise, trauma, excessive heat exposure.	Induces Vāta Prakopa and Mārga Avarod ha.

Contemporary Correlation

Contemporary literature well documents the correlation between Vātarakta and gout (or gouty arthritis) [5, 8]. However, direct equivalence cannot be established absolutely.

Table 9: Classical Vātarakta versus Contemporary Gout

Parameter	Classical Vātarakta	Contemporary Gout (Level IV)
Primary Etiology	Diet/Lifestyle → Vāta & Rakta vitiation.	Purine-rich diet/genetics → Hyperuricemia.
Pathophysi ology	Mārga Avarodha (Vascular/channe l obstruction).	Monosodium urate (MSU) crystal deposition triggering innate immune response [8].

Parameter	Classical Vātarakta	Contemporary Gout (Level IV)
Onset Site	Pādamūla (Feet) and Karamūla (Hands).	1st Metatarsophalangeal joint (Podagra).
Progression	Superficial (Uttāna) to Deep (Gambhīra).	Asymptomatic hyperuricemia → Acute flare → Intercritical gout → Chronic tophaceous gout [9].
Managemen t Focus	Cleansing Rakta, pacifying Vāta, restoring channel patency.	Lowering serum urate, reducing inflammation (NSAIDs, Colchicine, Urate-lowering therapy) [10].

Critical Assessment: While the clinical phenotype (acute, severe pain, predilection for extremities, dietary triggers) aligns perfectly with gout, the classical Samprāpti of Vātarakta encompasses a broader spectrum. It conceptually includes components of peripheral vascular disease, elderly-onset rheumatoid arthritis, and systemic inflammatory cascades driven by metabolic syndrome [11, 12].

Conceptual Model**Table 10: Direct textual evidence versus conceptual interpretation**

Pathologic al Stage	Direct Textual Evidence (Level I)	Conceptual Interpretati on (Level III)	Contempora ry Biomedical (Level IV)
Initiation	Vāta and Rakta become aggravated by specific Nidānas.	Metabolic overload plus mechanical stress.	Purine dysmetabolis m leading to hyperuricemi a.

Pathological Stage	Direct Textual Evidence (Level I)	Conceptual Interpretation (Level III)	Contemporary Biomedical (Level IV)
Interaction	Rakta obstructs the path of Vāta (Mārga Avarodha).	Inflammatory stasis and impaired microcirculation.	Monosodium Urate (MSU) crystallization causing endothelial distress and inflammatory cytokine release ^[13] .
Localization	Settles in Pādāmūla.	Gravity and poor distal vascular return favor distal joints.	Lower temperatures in peripheral joints decrease MSU solubility, favoring precipitation ^[14] .

Figure 1: Classical Samprāpti of Vātarakta

[Nidāna Sevana] ---> [Simultaneous aggravation of Vāta & Rakta] ---> [Mārga Avarodha in Srotas] ---> [Vāta-Rakta Saṁmūrchanā] ---> [Sthāna Saṁśraya in Pādāmūla] ---> [Vyakti: Acute Vātarakta]

Figure 2: Charaka-centric conceptual model of Vāta-Rakta interaction

[Vāta (Loss of Gati/Movement)] <==== (Mutual Obstruction) =====> [Rakta (Loss of Fluidity/Increased Toxicity)]

Result: Intense neuro-vascular pain and rapid structural damage.

Figure 3: Integrated Bṛhat-trayī model linking Nidāna → Samprāpti → Bheda → Chikitsā

[Dietary Toxins] ---> [Rakta Duṣṭi] ---> [Uttāna Avasthā] ---> [Therapy: Lepa, Raktamokṣaṇa, Mild Śodhana] Deep/Chronic Progression] ---> [Gambhīra

Avasthā] ---> [Therapy: Basti, Gudūcī, Deep Snehana]

Discussion :

The discussion critically interprets the findings without reiterating the results:

1. Distinct Disease Entity: Charaka describes Vātarakta separately from Vātavyādhi because its treatment paradigm is paradoxical. Standard Vātavyādhi requires heavy unctuous and heating therapies, which would disastrously aggravate the inflamed Rakta in Vātarakta.

2. Centrality of Vāta and Rakta: The disease is fundamentally an interaction. Vāta provides the vector (movement and pain), while Rakta provides the medium of obstruction and inflammation.

3. Mārga Avarodha: This is the pathophysiological core. Without obstruction, the Doṣas would not localize so destructively in the distal extremities. The classical text states that once the obstruction is cleared (via Raktamokṣaṇa or Virecana), Vāta resumes its normal Gati.

4. Clinical Variability: The symptoms shift drastically based on the dominant Doṣa. Pitta-dominant presentations resemble acute fiery gout flares, while Vāta-dominant presentations exhibit extreme neuropathic-like pain and stiffness.

5. Charaka's Distinctive Contribution: Charaka elevates the disease from a mere localised joint issue to a profound systemic metabolic and circulatory disorder requiring individualised, systemic detox (Basti and Virecana).

6. Modern Gout Overlap: While gout perfectly mirrors the metabolic and distal joint elements of Vātarakta, interpreting Vātarakta solely as gout

ignores the explicit classical inclusion of complex neuro-vascular pathologies.

7. Limitations of Retrospective Interpretation:

Translating ancient pathophysiological terms directly into modern biomedical concepts risks anachronism. Rakta is not merely "blood" but a complex, life-sustaining tissue that incorporates metabolic and immune functions.

Novelty And Research Implications :

Research Gap: Current literature offers mostly superficial correlations between Vātarakta and gout, often overlooking the profound structural differences in etiology and pathogenesis described in the Bṛhat-trayī. There is an acute lack of structured Sampṛāpti reconstruction that distinctly links the concept of *Mārga Avarodha* with targeted therapeutic rationale (like *Basti* and *Raktamokṣaṇa*).

Novelty: This manuscript provides an original, Charaka-centric conceptual model that maps the bidirectional pathology of Vāta and Rakta, explicitly separating classical textual statements from retrospective biomedical mapping.

Limitations :

This study is strictly a conceptual and textual analysis. The pathophysiological linkages and contemporary correlations synthesized herein require validation through rigorous, prospective clinical trials utilizing standardized objective parameters (e.g., Doppler ultrasound for vascular flow, inflammatory biomarkers) alongside classical Ayurvedic diagnostic tools.

Future Research Directions :

Future studies should investigate the specific biochemical impact of classical Vātarakta therapies (e.g., Gudūcī and Kṣīra Basti) on inflammatory cytokines, serum urate reduction, and endothelial function in patients diagnosed with both Vātarakta and gouty arthritis.

Conclusion :

Vātarakta, as illuminated by the Bṛhat-trayī and specifically elevated by Charaka, is a sophisticated clinico-pathological entity defined by the destructive synergy of Vāta and Rakta. The disease fundamentally pivots on the principle of *Mārga Avarodha*—a metabolic and physical obstruction that dictates its distal-to-proximal progression. By establishing a direct linkage between the depth of pathogenesis (*Uttāna* vs. *Gambhīra*) and stage-specific therapeutic interventions (*Raktamokṣaṇa*, *Virecana*, *Basti*), Ayurvedic clinical literature offers a highly advanced, highly individualized approach to systemic inflammatory arthropathies that extends beyond the contemporary biomedical confines of mere hyperuricemia.

Declarations :

Conflict of Interest: The author declares no conflicts of interest.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions: VBK conceptualized the study, performed the textual analysis, drafted the manuscript, and approved the final version.

Data Availability: All classical textual data analyzed during this study are included in this

published article.

Ethical Statement: Not applicable, as this is a conceptual and textual literature review not involving human or animal subjects.

References :

1. Sharma PV, translator. Charaka Samhita of Agnivesha (Text with English Translation). Vol 2. Varanasi: Chaukhambha Orientalia; 2014. (Cikitsā Sthāna 29).
2. Shastri KA, editor. Sushruta Samhita of Maharshi Sushruta. Varanasi: Chaukhambha Sanskrit Sansthan; 2014. (Nidāna Sthāna 1, Cikitsā Sthāna 5).
3. Murthy KRS, translator. Ashtanga Hridayam of Vagbhata. Vol 2. Varanasi: Krishnadas Academy; 2016. (Nidāna Sthāna 16, Cikitsā Sthāna 22).
4. Khot GA, Yadav SM. Vatarakta in Ayurveda: Classical concepts, contemporary correlation with gout and evidence-based management. World J Pharm Res. 2026;15(19):117-131.
5. Dalal S, et al. Gout. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.
6. Ramachandran AP, Prasad SM, Prasad UN, Jonah S. A comparative study of Kaishora Guggulu and Amrita Guggulu in the management of Utthana Vatarakta. AYU. 2010;31(3):410-415.
7. Sharma R, Amin H, Galib, Prajapati PK. Therapeutic attributes of Guduchi (Tinospora cordifolia). AYU. 2013;34(1):16-20.
8. Ahn EY, So MW. The pathogenesis of gout. J Rheum Dis. 2024;32(1):8-16.
9. Qaseem A, et al. Clinical Guidelines for the Management of Gout. Ann Intern Med. 2025;178(3):23-35.
10. Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):210.
11. Kurande V. Case Report on the Ayurvedic Management of Vatarakta w.s.r to Elderly Onset Rheumatoid Arthritis. Int J Res Ayurveda Allied Sci. 2026.
12. Deshpande SV, Deshpande VS, Potdar SS. Effect of panchakarma and Ayurvedic treatment in postpartum rheumatoid arthritis (Amavata): A case study. J Ayurveda Integr Med. 2017;8(1):42-44.
13. Jin M. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17(2):656-669.
14. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.

15. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-328.

16. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-1798.

17. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1):31-41.

ISSN: 2584-2757

DOI :10.5281/zenodo.23435217

Dr. Vishwanath Kakde Inter. J.Digno. and Research

This work is licensed under Creative Commons Attribution 4.0 License



Submission Link : <http://www.ijdrindia.com>

प्रज्वालितो ज्ञानमयः प्रदीपः ॥



Benefits of Publishing with us

- Fast peer review process
- Global archiving of the articles
- Unrestricted open online access
- Author retains copyright
- Unique DOI for all articles

<https://ijdrindia.com>